PDCD1 and breast cancer: Despite the demonstrated potency of PD-1/PD-L1 inhibitors, the clinical outcomes in BC patients remain suboptimal, primarily attributed to insufficient tumor-infiltrating lymphocyte density and hypoxia-induced immunosuppressive tumor immune microenvironments (TIME).